Retatrutide has emerged as a new medication in the fight against obesity. This revolutionary drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By activating these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimat